» Articles » PMID: 22195691

Predictors of Clinical Success in a Multidisciplinary Model of Atopic Dermatitis Treatment

Overview
Date 2011 Dec 27
PMID 22195691
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Atopic dermatitis (AD) is one of the most common pediatric skin disorders. Because treatment involves allergen avoidance, dietary changes, and behavior modification, multidisciplinary treatment models have been used to complement conventional medication therapy. However, predictors of clinical response in these multidisciplinary models have not been studied. This study examined factors associated with a reduction in AD severity in a multidisciplinary outpatient pediatric AD treatment program providing medical, nutritional, and behavioral support. Data were collected from 170 patients between 2001 and 2006. The Eczema Area and Severity Index (EASI) score was determined at the time of each visit. Using a logistic regression model, we investigated the association of baseline demographic and clinical characteristics with clinical outcome. We also analyzed the association between improvement in the EASI score and behavioral changes. One hundred thirty-eight patients had significantly improved EASI scores, and 32 patients were nonresponders. Responders had a median improvement of 79% in their EASI score, whereas nonresponders had a 53% worsening of their EASI score (p < 0.0001) and a significantly worse absolute EASI score (p < 0.001). Predictors of clinical success included baseline EASI score, baseline age, and improved parental adherence to treatment recommendations. Improvement in the EASI score significantly correlated with quality-of-life measures: decreased itching and scratching, difficulty sleeping, and parental concerns about side effects. A multidisciplinary model of AD treatment has the best clinical outcomes in younger patients with severe AD. Ensuring parental compliance with treatment recommendations is important for clinical response.

Citing Articles

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis.

Silverberg J, Hong H, Calimlim B, Lee W, Teixeira H, Collins E Dermatol Ther (Heidelb). 2023; 13(10):2247-2264.

PMID: 37658223 PMC: 10539231. DOI: 10.1007/s13555-023-01000-3.


Sleep Disturbances in Children With Atopic Dermatitis: A Scoping Review.

Lee D, Gui X, Mukovozov I, Fleming P, Lynde C J Cutan Med Surg. 2023; 27(2):157-164.

PMID: 36880965 PMC: 10068401. DOI: 10.1177/12034754231159337.


Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis.

Silverberg J, Hong H, Thyssen J, Calimlim B, Joshi A, Teixeira H Dermatol Ther (Heidelb). 2022; 12(5):1181-1196.

PMID: 35435637 PMC: 9110624. DOI: 10.1007/s13555-022-00721-1.


Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.

Luger T, Hebert A, Zaenglein A, Silverberg J, Tan H, Ports W Paediatr Drugs. 2022; 24(2):175-183.

PMID: 35292919 PMC: 8940811. DOI: 10.1007/s40272-021-00490-y.


Educational intervention and atopic dermatitis: impact on quality of life and treatment.

Muzzolon M, Imoto R, Canato M, Abagge K, Carvalho V Asia Pac Allergy. 2021; 11(2):e21.

PMID: 34007831 PMC: 8103006. DOI: 10.5415/apallergy.2021.11.e21.